



## Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 5, 2024

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- [Dyne Therapeutics, Inc.](https://www.dyne-tx.com) (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42<sup>nd</sup> Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m. ET).

A live webcast will be available in the Investors & Media section of Dyne's website at <https://investors.dyne-tx.com/news-and-events/events-and-presentations> and a replay will be accessible for 30 days following the presentation.

### About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit <https://www.dyne-tx.com>, and follow us on [X](#), [LinkedIn](#) and [Facebook](#).

### Contact:

Amy Reilly  
[areilly@dyne-tx.com](mailto:areilly@dyne-tx.com)  
857-341-1203